This study may provide additional scientific rationale to support the recent trend that giving hormone treatment early on is better than waiting, Reiter said. Early hormone treatment in this group of men might allow them to live longer. High levels of androgen receptor in the primary tumor might also predict which cancers are more likely to spread despite initial surgery or radiation.
This strategy could be particularly effective in high risk men, those with large primary tumors, high Gleason scores and those that have lymph node involvement at diagnosis.
Prostate cancer is the most common cancer in men in the United States. This year alone, more than 218,000 men will be diagnosed with prostate cancer. About 27,000 men will die from the disease.
Reiter and his team will next seek to understand the mechanism by which androgen receptor overexpression is causing the cancer to spread. If they can uncover the mechanism, they might find new and better targets for drug therapy in addition to targeting the androgen receptor.
'/>"/>
| Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Source:Eurekalert |